Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Current Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Total Current Liabilities for 11 consecutive years, with $61.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 14.62% to $61.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $61.8 million, a 14.62% decrease, with the full-year FY2024 number at $77.2 million, up 22.16% from a year prior.
  • Total Current Liabilities was $61.8 million for Q3 2025 at Editas Medicine, down from $65.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $77.2 million in Q4 2024 to a low of $36.4 million in Q2 2022.
  • A 5-year average of $59.4 million and a median of $61.8 million in 2025 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 44.83% in 2022, then surged 56.58% in 2023.
  • Editas Medicine's Total Current Liabilities stood at $46.9 million in 2021, then grew by 28.21% to $60.1 million in 2022, then rose by 5.17% to $63.2 million in 2023, then grew by 22.16% to $77.2 million in 2024, then decreased by 20.01% to $61.8 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Total Current Liabilities are $61.8 million (Q3 2025), $65.9 million (Q2 2025), and $73.1 million (Q1 2025).